Journals / Anadolu Kardiyoloji Dergisi / 2010 / Cilt: 10 - Sayı: 3

Koroner arter hastalığı şiddetinin apolipoprotein E gen polimorfizmi ile ilişkisi

Relationship between severity of coronary artery disease and apolipoprotein E gene polymorphism

Pages
202–208
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Methods: Overall, 53 Turkish patients, aged 54±11years defined by coronary angiography were included in this cross-sectional study.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To explore the possible contribution of the apolipoprotein (apo) E polymorphisms to the extent and severity of coronary artery disease (CAD) related to lipid metabolism.
📊
Key Findings & Data:Methods: Overall, 53 Turkish patients, aged 54±11years defined by coronary angiography were included in this cross-sectional study.
💡
Conclusion & Impact:These associations with severity were mediated not only by changes in lipid metabolism but may be also by other mechanisms in CAD patients.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To explore the possible contribution of the apolipoprotein (apo) E polymorphisms to the extent and severity of coronary artery disease (CAD) related to lipid metabolism. Methods: Overall, 53 Turkish patients, aged 54±11years defined by coronary angiography were included in this cross-sectional study. Reardon’s coronary artery scoring was used. Serum lipids were measured with enzymatic colorimetric methods. Apolipoproteins were measured with nephelometry. Apolipoprotein E gene polymorphisms were determined by the reverse hybridization method. Statistical analyses were performed using one-way ANOVA, Kruskal-Wallis and Chi- square tests. Results: The genotype frequencies were 7.5% for E2/E3, 77.4% for E3/E3 and 15.1% for E3/E4. The E2 allele frequency was slightly lower than E4 allele. There were no significant differences between apo E2/E3, E3/E3 and E3/E4 genotypes for severity scorings (26, 41 and 32 respectively, p=0.30) and extent scorings (3.2, 5.5, 4.5, p=0.17). It was found that the most of patients who had E2/3 and E3/4 alleles had low severity scores. On the other hand, there were no significant score difference for patients who had E3/3 alleles. Lipids were not significantly different among the different genotypes. The E3 allele was associated with high apo B levels compared with E2 and E4 genotypes. It was found that severity and extent of disease were not related with lipid metabolism. Conclusion: We concluded that there were no statistically significant differences between genotypes for extent and severity scorings, but the apo E3 allele is associated with more severe disease than E2 allele. These associations with severity were mediated not only by changes in lipid metabolism but may be also by other mechanisms in CAD patients.

Özet

Amaç: Apolipoprotein (apo) E polimorfizmlerinin lipid metabolizması ile de ilişkili olarak koroner arter hastalığının yaygınlık ve şiddetine olan olası katkısını tespit etmek. Yöntemler: Koroner anjiyografi ile tanıları konmuş, yaşları 54±11 olan 53 Türk hasta bu enine-kesitsel çalışmaya alındı. Reardon'ın koroner arter skorlaması kullanıldı. Serumda lipidler enzimatik kolorimetrik yöntemle ölçüldü. Apolipoproteinler nefelometri ile ölçüldü. Apolipoprotein E gen polimorfizmi reverse-hybridization yöntemi ile tespit edildi. İstatistiksel analizde tek-yönlü ANOVA, Kruskal-Wallis ve Ki-kare testleri kullanıldı. Bulgular: Genotip sıklıkları E2/E3 için %7.5, E3/E3 için %77.4 ve E3/E4 için %15.1 olarak bulundu. E2 allel sıklığı E4 alleline göre daha düşüktü. İstatistiksel olarak apo E2/E3, E3/E3 ve E3/E4 genotipleri arasında şiddet skorları (26, 41 ve 32 sırasıyla, p=0.30) ve yaygınlık skorları (3.2, 5.5, 4.5, p=0.17) açısından anlamlı fark bulunmadı. Apolipoprotein E2/3 ve E3/4 allellerine sahip hastaların çoğunda düşük şiddet skorları bulunurken, diğer yanda E3/3 alleline sahip hastalarda anlamlı skor farkı yoktu. Lipidler değişik genotipler arasında farklılık göstermedi. E2 ve E4 genotiplerine nazaran E3 alleli yüksek apo B seviyeleri ile birlikteydi. Hastalık şiddet ve yaygınlığı lipid metabolizması ile ilişkili bulunmadı. Sonuç: Hastalığın yaygınlık ve şiddetinde genotipler arasında istatistiksel olarak anlamlı fark görülmediği sonucuna varıldı, fakat apo E3 alleli E2’ye göre hastalığın daha şiddetli oluşu ile birlikteydi. Koroner arter hastalığında hastalığın şiddeti sadece lipid metabolizması ile ilişkili olarak değil diğer mekanizmalar ile de açıklanabilir.

🔖

Cite This Article

ATAY, A., KÖSEOĞLU, M., İNCE, A. F. D., DEVECİ, E., YEŞİL, M. (2022). Koroner arter hastalığı şiddetinin apolipoprotein E gen polimorfizmi ile ilişkisi. Anadolu Kardiyoloji Dergisi, Cilt: 10 - Sayı: 3, 202–208. https://ajindex.com/articles/436782

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Betteridge DJ, Illingworth DR, Shepherd J, editors. Lipoproteins in health and disease. New York: Oxford University; 1999
  2. Onat A. Lipids, lipoproteins and apolipoproteins among Turks and impact on coronary heart disease. Anadolu Kardiyol Derg 2004; 4: 236-45. PMid:15355827 3. Bersot TP, Palaoglu KE, Mahley RW. Managing dyslipidemia in Turkey: suggested guidelines for a population characterized by low levels of high density lipoprotein cholesterol. Anadolu Kardiyol Derg 2002; 2: 315-22. PMid:12460830 4. Vogel T, Guo NH, Guy R, Drezlich N, Krutzsch HC, Blake DA, et al. Apolipoprotein E: A potent inhibitor of endothelial and tumor cell proliferation. J Cell Biochem 1994; 54: 299-308. doi:10.1002/jcb.240540306 PMid:8200910 5. Kolovou GD, Anagnostopoulou KK, Cokkinos DV. Apolipoprotein E gene polymorphism and myocardial infarction. Int J Cardiol 2009; 133: 264-5. doi:10.1016/j.ijcard.2007.11.024 PMid:18190985 6. Eichner JE, Dunn ST, Perveen G, Thompson DM, Stewart KE, Stroehla BC. Apolipolipoprotein E polymorphism and cardiovascular cisease: a HuGE review. Am J Epidemiol 2002; 155: 487-95. doi:10.1093/aje/155.6.487 PMid:11882522 7. Sing CF, Davignon J. Role of the apolipoprotein E polymorphism in determining normal plasma lipid and lipoprotein variation. Am J Hum Genet 1985; 37: 268-85. PMid:3985008 PMCid:1684560 8. Gajra B, Candlish JK, Saha N, Mak JW, Tay JS. Effect of apolipoprotein E variants on plasma lipids and apolipoproteins in the Orang Asli ('Aborigines') of Malaysia. Hum Hered 1994; 44: 209-13. doi:10.1159/000154219 PMid:8056432 9. Gajra B, Candlish JK, Saha N, Heng CK, Soemantri AG, Tay JS. Influence of polymorphisms for apolipoprotein B (ins/del XbaI, EcoRI) and apolipoprotein E on serum lipids and apolipoproteins in a Javanese population. Genet Epidemiol 1994;11:19-27. doi:10.1002/gepi.1370110103 PMid:8013886 10. Reilly SL, Ferrell RE, Sing CF. The gender-specific apolipoprotein E genotype influence on the distribution of plasma lipids and apolipoproteins in the population of Rochester, Minn, III: correlations and covariances. Am J Hum Genet 1994;55:1001-18. PMid:7977338 PMCid:1918313 11. Tiret L, De Knijff P, Menzel HJ, Ehnholm C, Nicaud V, Havekes LM. Apo E polymorphism and predisposition to coronary heart disease in youths of different European populations: the EARS Study. Arterioscler Thromb 1994; 14: 1617-24. PMid:7918312 12. O'Brien KD, Deeb SS, Ferguson M, McDonald TO, Allen MD, Alpers CE, et al. Apolipoprotein E localization in huma